Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality

Asim Saha, Roddy S. O'Connor, Govindarajan Thangavelu, Scott B. Lovitch, Durga Bhavani Dandamudi, Caleph B. Wilson, Benjamin G. Vincent, Victor Tkachev, Jan M. Pawlicki, Scott N. Furlan, Leslie S. Kean, Kazutoshi Aoyama, Patricia A. Taylor, Angela Panoskaltsis-Mortari, Rocio Foncea, Parvathi Ranganathan, Steven M. Devine, Joel S. Burrill, Lili Guo, Catarina SacristanNathaniel W. Snyder, Ian A. Blair, Michael C. Milone, Michael L. Dustin, James L. Riley, David A. Bernlohr, William J. Murphy, Brian T. Fife, David H. Munn, Jeffrey S. Miller, Jonathan S. Serody, Gordon J. Freeman, Arlene H. Sharpe, Laurence A. Turka, Bruce R. Blazar

Research output: Contribution to journalArticlepeer-review

75 Scopus citations


Programmed death ligand-1 (PD-L1) interaction with PD-1 induces T cell exhaustion and is a therapeutic target to enhance immune responses against cancer and chronic infections. In murine bone marrow transplant models, PD-L1 expression on host target tissues reduces the incidence of graft-versus-host disease (GVHD). PD-L1 is also expressed on T cells; however, it is unclear whether PD-L1 on this population influences immune function. Here, we examined the effects of PD-L1 modulation of T cell function in GVHD. In patients with severe GVHD, PD-L1 expression was increased on donor T cells. Compared with mice that received WT T cells, GVHD was reduced in animals that received T cells from Pdl1-/- donors. PD-L1-deficient T cells had reduced expression of gut homing receptors, diminished production of inflammatory cytokines, and enhanced rates of apoptosis. Moreover, multiple bioenergetic pathways, including aerobic glycolysis, oxidative phosphorylation, and fatty acid metabolism, were also reduced in T cells lacking PD-L1. Finally, the reduction of acute GVHD lethality in mice that received Pdl1-/- donor cells did not affect graft-versus-leukemia responses. These data demonstrate that PD-L1 selectively enhances T cell-mediated immune responses, suggesting a context-dependent function of the PD-1/PD-L1 axis, and suggest selective inhibition of PD-L1 on donor T cells as a potential strategy to prevent or ameliorate GVHD.

Original languageEnglish (US)
Pages (from-to)2642-2660
Number of pages19
JournalJournal of Clinical Investigation
Issue number7
StatePublished - Jul 1 2016

Bibliographical note

Funding Information:
We thank Christopher Lees and colleagues of B.R. Blazar's laboratory for technical assistance, S. Davis (University of Oxford, Oxford, UK) for human PD-L1, and S. Garrett and S. Almo (Einstein School of Medicine, New York, NY) for data on interspecies interactions. This study was supported in part by NIH grants HL056067 (to B.R. Blazar), AI034495 (to B.R. Blazar), AI056299 (to B.R. Blazar), and AI043542 (to M.L. Dustin), and the Wellcome Trust (to M.L. Dustin).


Dive into the research topics of 'Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality'. Together they form a unique fingerprint.

Cite this